Comprehensive analysis of kinase inhibitor selectivity
暂无分享,去创建一个
Mindy I. Davis | L. Wodicka | P. Zarrinkar | S. Herrgård | D. K. Treiber | P. Ciceri | Jeremy P Hunt | G. Pallares | M. Hocker | Mindy Davis | Gabriel Pallares
[1] T. Hunter,et al. The Protein Kinase Complement of the Human Genome , 2002, Science.
[2] P. Cohen,et al. The specificities of protein kinase inhibitors: an update. , 2003, The Biochemical journal.
[3] Krystal J Alligood,et al. A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib) , 2004, Cancer Research.
[4] J. Warmus,et al. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition , 2004, Nature Structural &Molecular Biology.
[5] A. Ryan,et al. Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors , 2004, Oncogene.
[6] L. Wodicka,et al. A small molecule–kinase interaction map for clinical kinase inhibitors , 2005, Nature Biotechnology.
[7] N. Gray,et al. Rational design of inhibitors that bind to inactive kinase conformations , 2006, Nature chemical biology.
[8] Andrew I Su,et al. An efficient rapid system for profiling the cellular activities of molecular libraries. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[9] Helge Weissig,et al. Functional interrogation of the kinome using nucleotide acyl phosphates. , 2007, Biochemistry.
[10] S. Knapp,et al. A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases , 2007, Proceedings of the National Academy of Sciences.
[11] Bernhard Kuster,et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors , 2007, Nature Biotechnology.
[12] Gavin Harper,et al. Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. , 2008, Journal of medicinal chemistry.
[13] P. Zarrinkar,et al. High-throughput kinase profiling as a platform for drug discovery , 2008, Nature Reviews Drug Discovery.
[14] Mindy I. Davis,et al. A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.
[15] E. Solary,et al. AC 220 is a uniquely potent and selective inhibitor of FLT 3 for the treatment of acute myeloid leukemia ( AML ) , 2009 .
[16] G. Superti-Furga,et al. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells , 2009, Leukemia.
[17] Stephen K Burley,et al. SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo , 2009, Molecular Cancer Therapeutics.
[18] Hans Bitter,et al. Identification of a Kinase Profile that Predicts Chromosome Damage Induced by Small Molecule Kinase Inhibitors , 2009, PLoS Comput. Biol..
[19] P. Zarrinkar,et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). , 2009, Blood.
[20] Taebo Sim,et al. Small Molecule Kinase Inhibitors Provide Insight into Mps1 Cell Cycle Function , 2010, Nature chemical biology.
[21] K. Shokat,et al. Targeting the cancer kinome through polypharmacology , 2010, Nature Reviews Cancer.
[22] Daniel K Treiber,et al. Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry. , 2010, Chemistry & biology.
[23] C. Grütter,et al. Fluorophore labeling of the glycine-rich loop as a method of identifying inhibitors that bind to active and inactive kinase conformations. , 2010, Journal of the American Chemical Society.
[24] Yong Huang,et al. Kinase inhibition-related adverse events predicted from in vitro kinome and clinical trial data , 2010, J. Biomed. Informatics.
[25] Ting Zhou,et al. Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysis , 2010, Bioinform..
[26] B. Hasinoff,et al. The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro. , 2010, Toxicology and applied pharmacology.
[27] N. Gray,et al. Characterization of a selective inhibitor of the Parkinson’s disease kinase LRRK2 , 2011, Nature chemical biology.
[28] Randall W King,et al. High-throughput kinase profiling: a more efficient approach toward the discovery of new kinase inhibitors. , 2011, Chemistry & biology.
[29] Stephen R. Johnson,et al. Trends in kinase selectivity: insights for target class-focused library screening. , 2011, Journal of medicinal chemistry.
[30] P. Hajduk,et al. Navigating the kinome. , 2011, Nature chemical biology.